Asciminib

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 362 publications

Treatment strategies for chronic-phase chronic myeloid leukemia in 2026

Treatment strategies for chronic-phase chronic myeloid leukemia in 2026

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: October 28, 2026

Characterization of Adverse Cutaneous Effects in the Setting of Ponatinib, Bosutinib, and Asciminib for Chronic Myeloid Leukemia Patients.

Characterization of Adverse Cutaneous Effects in the Setting of Ponatinib, Bosutinib, and Asciminib for Chronic Myeloid Leukemia Patients.

Journal: Hematological oncology

Published: September 30, 2026

Revisiting Asciminib Resistance: From Binding Affinity to Allosteric Disruption in BCR::ABL1 Leukemias.

Revisiting Asciminib Resistance: From Binding Affinity to Allosteric Disruption in BCR::ABL1 Leukemias.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: September 08, 2026

Twenty-Five Years of CML Therapy in India: A Model for Precision Oncology in a Resource-Constrained Setting.

Twenty-Five Years of CML Therapy in India: A Model for Precision Oncology in a Resource-Constrained Setting.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 06, 2026

Asciminib After Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia: A Multicenter Real-World Experience.

Asciminib After Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia: A Multicenter Real-World Experience.

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 25, 2026

Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.

Nilotinib in chronic myeloid leukemia: clinical value, real-world challenges, and the potential of nilotinib tablets to improve therapeutic outcomes.

Journal: Expert review of hematology

Published: August 12, 2026

First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

Journal: Haematologica

Published: August 10, 2026

Design, synthesis, molecular docking and anticancer activity of novel N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives.

Design, synthesis, molecular docking and anticancer activity of novel N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives.

Journal: RSC advances

Published: August 07, 2026

A novel BCR::ABL1 I502T mutation associated with acquired asciminib resistance in CML.

A novel BCR::ABL1 I502T mutation associated with acquired asciminib resistance in CML.

Journal: Leukemia research

Published: August 05, 2026

The evolving landscape of tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia: A 25-year journey.

The evolving landscape of tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia: A 25-year journey.

Journal: Blood reviews

Published: July 23, 2026

Connecting asciminib tolerability to long-term treatment persistence. Comment on: "Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia".

Connecting asciminib tolerability to long-term treatment persistence. Comment on: "Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia".

Journal: Haematologica

Published: July 15, 2026

Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites.

Allosteric kinase inhibition in hematological malignancies: from asciminib to emerging regulatory sites.

Journal: Biochemical pharmacology

Published: July 10, 2026

Showing 1-12 of 362

Last Updated: 11/08/2026